Drug Profile
Research programme: muscle relaxants and reversal agents - Avera Pharmaceuticals
Alternative Names: AV 002Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cornell University
- Class Fumarates; Tetrahydroisoquinolines
- Mechanism of Action Neuromuscular blocking agents; Neuromuscular nondepolarising agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Muscle hypertonia; Neuromuscular blockade
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertonia in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuromuscular-blockade in USA
- 02 Apr 2008 Preclinical development is ongoing